Does Mounjaro (tirzepatide) actually change the way your body burns calories?

A fascinating new human study presented at ENDO 2026 suggests it may do more than suppress appetite. Researchers studying brown adipose tissue (brown fat) found that tirzepatide increased detectable brown fat activity after 24 weeks of treatment. But what exactly does that mean for metabolism, weight loss, and long-term metabolic health? In this video, we’re decoding the science behind brown fat, beige fat, mitochondrial function, and the possibility that GLP-1 medications may influence energy expenditure in ways we haven’t fully understood. 🔬 WHAT WE DISCUSS: * What is brown adipose tissue, and why does it burn calories? * The difference between white fat, brown fat, and beige fat. * The 2026 TABFAT trial: what researchers actually discovered. * Why detectable brown fat activity increased from 41.2% to 64.7% of participants. * What UCP1 and mitochondrial uncoupling have to do with burning energy. * Research involving mirabegron and cold exposure. * What animal studies reveal about tirzepatide and thermogenesis. * Could GLP-1 medications influence energy expenditure beyond appetite suppression? * What we still don’t know about brown fat activation and long-term weight maintenance. AN IMPORTANT DISTINCTION: Increased brown fat activity does not necessarily mean a clinically meaningful increase in total calories burned. In TABFAT, researchers did not demonstrate a statistically significant between-group increase in resting energy expenditure. This is early but fascinating research, and we need larger, longer human studies. I believe the future of obesity research will involve understanding not only how much we eat, but also how our adipose tissue, mitochondria, nervous system, and metabolic pathways regulate energy. That’s the science worth watching. If you enjoy evidence-based endocrinology without the hype, subscribe to the channel! ABOUT DR. SUSAN BRIAN I’m Susan Brian, MD, a board-certified endocrinologist and menopause specialist with a clinical research background. I discuss emerging research in obesity, diabetes, menopause, metabolic health, and GLP-1 medications. My goal is to help you understand the science behind the headlines. SCIENTIFIC REFERENCES 1. Herman R, et al. TABFAT Trial. ENDO 2026. Tirzepatide and brown adipose tissue activation. Endocrine Society. 2. Herman R, et al. TABFAT trial rationale and design. Trials. 2025. DOI: 10.1186/s13063-025-09045-9. 3. Samms RJ, et al. Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Molecular Metabolism. 2022. DOI: 10.1016/j.molmet.2022.101550. 4. Cypess AM, et al. Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist. Cell Metabolism. 2015. DOI: 10.1016/j.cmet.2014.12.009. 5. Hanssen MJW, et al. Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus. Nature Medicine. 2015. DOI: 10.1038/nm.3891. DISCLAIMER: This video is for educational and informational purposes only and is not intended to provide individual medical advice, diagnose or treat any condition, or replace a discussion with your healthcare professional. Research findings are evolving, and medications should only be used under appropriate medical supervision. #Mounjaro #Tirzepatide #BrownFat #GLP1 #ObesityResearch #MetabolicHealth #Endocrinology #WeightLossResearch #Zepbound #DrSusanBrian